vs
CareDx, Inc.（CDNA）与Purple Innovation, Inc.（PRPL）财务数据对比。点击上方公司名可切换其他公司
Purple Innovation, Inc.的季度营收约是CareDx, Inc.的1.2倍（$140.7M vs $117.7M），CareDx, Inc.净利率更高（2.4% vs -2.3%，领先4.7%），CareDx, Inc.同比增速更快（39.0% vs 9.1%），CareDx, Inc.自由现金流更多（$514.0K vs $-7.8M），过去两年CareDx, Inc.的营收复合增速更高（12.9% vs 8.3%）
CareDx是一家专注于器官移植领域的精准医疗企业，核心产品包括移植排斥反应监测诊断试剂、数字健康管理工具及配套临床服务，面向北美和欧洲市场的医疗机构及移植患者，助力提升术后患者生存质量。
Purple Carrot是一家总部位于马萨诸塞州尼达姆市的全植物性餐包品牌，由安迪·莱维特创立，每周为订阅用户提供预制餐品和自制餐包。据《大都会》2022年报道，对比美式标准餐食，该品牌每份餐包的碳排放量可降低72%，主打低碳环保的纯植物饮食方案。
CDNA vs PRPL — 直观对比
营收规模更大
PRPL
是对方的1.2倍
$117.7M
营收增速更快
CDNA
高出29.9%
9.1%
净利率更高
CDNA
高出4.7%
-2.3%
自由现金流更多
CDNA
多$8.3M
$-7.8M
两年增速更快
CDNA
近两年复合增速
8.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $117.7M | $140.7M |
| 净利润 | $2.8M | $-3.2M |
| 毛利率 | — | 41.9% |
| 营业利润率 | 1.0% | -1.6% |
| 净利率 | 2.4% | -2.3% |
| 营收同比 | 39.0% | 9.1% |
| 净利润同比 | — | 62.1% |
| 每股收益（稀释后） | $0.05 | $0.03 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CDNAPRPL
| Q1 26 | $117.7M | — | ||
| Q4 25 | $108.4M | $140.7M | ||
| Q3 25 | $100.1M | $118.8M | ||
| Q2 25 | $86.7M | $105.1M | ||
| Q1 25 | $84.7M | $104.2M | ||
| Q4 24 | $86.6M | $129.0M | ||
| Q3 24 | $82.9M | $118.6M | ||
| Q2 24 | $92.3M | $120.3M |
净利润CDNAPRPL
| Q1 26 | $2.8M | — | ||
| Q4 25 | $-4.1M | $-3.2M | ||
| Q3 25 | $1.7M | $-11.7M | ||
| Q2 25 | $-8.6M | $-17.3M | ||
| Q1 25 | $-10.4M | $-19.1M | ||
| Q4 24 | $87.7M | $-8.5M | ||
| Q3 24 | $-10.6M | $-39.2M | ||
| Q2 24 | $-4.6M | $27.0K |
毛利率CDNAPRPL
| Q1 26 | — | — | ||
| Q4 25 | — | 41.9% | ||
| Q3 25 | — | 42.8% | ||
| Q2 25 | — | 35.9% | ||
| Q1 25 | — | 39.4% | ||
| Q4 24 | — | 42.9% | ||
| Q3 24 | — | 29.7% | ||
| Q2 24 | — | 40.7% |
营业利润率CDNAPRPL
| Q1 26 | 1.0% | — | ||
| Q4 25 | -5.6% | -1.6% | ||
| Q3 25 | -0.2% | -10.2% | ||
| Q2 25 | -12.8% | -13.5% | ||
| Q1 25 | -15.8% | -13.9% | ||
| Q4 24 | 97.5% | -6.0% | ||
| Q3 24 | -16.6% | -39.5% | ||
| Q2 24 | -7.9% | -12.1% |
净利率CDNAPRPL
| Q1 26 | 2.4% | — | ||
| Q4 25 | -3.8% | -2.3% | ||
| Q3 25 | 1.7% | -9.9% | ||
| Q2 25 | -9.9% | -16.5% | ||
| Q1 25 | -12.2% | -18.4% | ||
| Q4 24 | 101.3% | -6.6% | ||
| Q3 24 | -12.8% | -33.1% | ||
| Q2 24 | -5.0% | 0.0% |
每股收益（稀释后）CDNAPRPL
| Q1 26 | $0.05 | — | ||
| Q4 25 | $-0.08 | $0.03 | ||
| Q3 25 | $0.03 | $0.11 | ||
| Q2 25 | $-0.16 | $0.16 | ||
| Q1 25 | $-0.19 | $0.18 | ||
| Q4 24 | $1.60 | $0.08 | ||
| Q3 24 | $-0.20 | $0.36 | ||
| Q2 24 | $-0.09 | $0.00 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $77.9M | $24.3M |
| 总债务越低越好 | — | $126.7M |
| 股东权益账面价值 | — | $-29.7M |
| 总资产 | $411.1M | $296.3M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CDNAPRPL
| Q1 26 | $77.9M | — | ||
| Q4 25 | $177.2M | $24.3M | ||
| Q3 25 | $194.2M | $32.4M | ||
| Q2 25 | $186.3M | $34.2M | ||
| Q1 25 | $230.9M | $21.6M | ||
| Q4 24 | $260.7M | $29.0M | ||
| Q3 24 | $240.9M | $23.4M | ||
| Q2 24 | $228.9M | $23.4M |
总债务CDNAPRPL
| Q1 26 | — | — | ||
| Q4 25 | — | $126.7M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $70.7M | ||
| Q3 24 | $0 | $50.8M | ||
| Q2 24 | $0 | — |
股东权益CDNAPRPL
| Q1 26 | — | — | ||
| Q4 25 | $303.1M | $-29.7M | ||
| Q3 25 | $311.1M | $-26.9M | ||
| Q2 25 | $327.4M | $-15.6M | ||
| Q1 25 | $379.3M | $1.3M | ||
| Q4 24 | $378.4M | $20.2M | ||
| Q3 24 | $273.2M | $28.0M | ||
| Q2 24 | $264.7M | $66.4M |
总资产CDNAPRPL
| Q1 26 | $411.1M | — | ||
| Q4 25 | $413.2M | $296.3M | ||
| Q3 25 | $432.3M | $302.1M | ||
| Q2 25 | $444.3M | $303.8M | ||
| Q1 25 | $489.6M | $293.8M | ||
| Q4 24 | $491.1M | $307.8M | ||
| Q3 24 | $477.0M | $309.3M | ||
| Q2 24 | $466.8M | $362.1M |
负债/权益比CDNAPRPL
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 3.50× | ||
| Q3 24 | 0.00× | 1.82× | ||
| Q2 24 | 0.00× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $4.3M | $-5.8M |
| 自由现金流经营现金流 - 资本支出 | $514.0K | $-7.8M |
| 自由现金流率自由现金流/营收 | 0.4% | -5.5% |
| 资本支出强度资本支出/营收 | — | 1.4% |
| 现金转化率经营现金流/净利润 | 1.54× | — |
| 过去12个月自由现金流最近4个季度 | — | $-41.9M |
8季度趋势，按日历期对齐
经营现金流CDNAPRPL
| Q1 26 | $4.3M | — | ||
| Q4 25 | $21.4M | $-5.8M | ||
| Q3 25 | $37.4M | $-968.0K | ||
| Q2 25 | $9.9M | $-4.0M | ||
| Q1 25 | $-26.6M | $-23.1M | ||
| Q4 24 | $21.9M | $6.8M | ||
| Q3 24 | $12.5M | $1.1M | ||
| Q2 24 | $18.9M | $-8.9M |
自由现金流CDNAPRPL
| Q1 26 | $514.0K | — | ||
| Q4 25 | — | $-7.8M | ||
| Q3 25 | — | $-1.8M | ||
| Q2 25 | — | $-7.0M | ||
| Q1 25 | — | $-25.3M | ||
| Q4 24 | — | $5.7M | ||
| Q3 24 | — | $101.0K | ||
| Q2 24 | — | $-11.0M |
自由现金流率CDNAPRPL
| Q1 26 | 0.4% | — | ||
| Q4 25 | — | -5.5% | ||
| Q3 25 | — | -1.5% | ||
| Q2 25 | — | -6.6% | ||
| Q1 25 | — | -24.3% | ||
| Q4 24 | — | 4.4% | ||
| Q3 24 | — | 0.1% | ||
| Q2 24 | — | -9.2% |
资本支出强度CDNAPRPL
| Q1 26 | — | — | ||
| Q4 25 | — | 1.4% | ||
| Q3 25 | — | 0.7% | ||
| Q2 25 | — | 2.8% | ||
| Q1 25 | — | 2.2% | ||
| Q4 24 | — | 0.8% | ||
| Q3 24 | — | 0.9% | ||
| Q2 24 | — | 1.7% |
现金转化率CDNAPRPL
| Q1 26 | 1.54× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 22.30× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.25× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -330.22× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CDNA
| Financial Results Total | $85.0M | 72% |
| Patient and digital solutions revenue | $16.0M | 14% |
| Product revenue | $10.3M | 9% |
| Other | $6.4M | 5% |
PRPL
| Cost Of Revenues | $81.7M | 58% |
| Other | $59.0M | 42% |
